will fda ban compounded semaglutide Zepbound copycats remain online despite FDA crackdown on off-brand Ozempic

In a 2-year trial involving patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with semaglutide 0.5 and 1 mg once weekly injections (3%) compared to placebo (1.8%)

Ben attributes this to several factors: Proven effectiveness in clinical trials and real-world use Social media and press coverage showcasing dramatic weight loss stories Advances in drug delivery, including long-acting formulations and oral options Expanding indications beyond diabetes to include obesity treatment Were in a situation where its the right molecule at the right time, Ben notes

The FDA has received adverse event reports specifically linked to compounded GLP-1 products involving incorrect dosing and concentration errors a risk entirely absent from the SURMOUNT trial data

But when he changed jobs, none of the plans offered by his new employer covered Wegovy

Updated June 2021

Whether its through weight loss or a subtle aesthetic tweak, these advancements empower people to take control of their lives in ways that werent possible before